Market Overview:
The global oxaliplatin injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for better treatment options, and technological advancements. Based on type, the global oxaliplatin injection market can be segmented into 10ml:50mg, 10ml:100mg, and other segments. The 10ml:50mg segment is expected to account for the largest share of the global oxaliplatin injection market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. Based on application, the global oxaliplatin injection market can be divided into ovarian cancer, breast cancer, SCLC (small cell lung cancer), and other segments. The ovarian cancer segment is expected to account for a major share of the global oxaliplatin injection market in 2018 and is projected grow at a CAGR of xx% duringthe forecast period from2018to2030.
Product Definition:
Oxaliplatin Injection is an anticancer drug that is used to treat various types of cancer, including colon cancer. It belongs to a class of drugs called platinum-based chemotherapy drugs, and works by interfering with the growth and spread of cancer cells.
10ml:50mg:
10ml:50mg, it's usage and growth factor in Oxaliplatin Injection market? By what route is the drug administered ? It can be given intravenously, orally or subcutaneously.
By which routes can it not be administered ? It cannot be administered intradermally (through the skin) because of its toxic nature.
10ml:100mg:
10ml:100mg is a form of oxaliplatin. It is used in the treatment of breast cancer and it's associated symptoms such as bone pain, appetite loss, diarrhea, fatigue and/or shortness of breath. 10 ml:100 mg contains 10 mCi (millicuries) of pure platinum with 100 mg of sodium thiosulphate which are both USP grade. The drug was approved by the U.
Application Insights:
Owing to the high prevalence of cancer, especially breast and lung cancer, this drug finds a wide range of applications in various other cancers such as ovarian and secondary brain tumors. Oxaliplatin is one of the most effective chemotherapeutic drugs for treating these types of cancers.
The breast cancer segment held around 40% share in 2015 owing to its high incidence rate globally coupled with awareness programs about early detection and treatment being conducted by various organizations such as World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR). The ovarian cancer segment is expected to witness lucrative growth during the forecast period due to increasing R&D initiatives by key players for developing new products with better efficacy & fewer side effects. This trend has led major pharmaceutical companies including Pfizer Inc., Novartis AG., sanofi-aventis ULC., Mylan N.V., etc.
Regional Analysis:
North America dominated the global oxaliplatin injection market in 2017. This is attributed to the presence of a large number of key players, high adoption rate for novel drugs, and availability of well-developed healthcare infrastructure. Moreover, increasing government funding for cancer research and development as well as commercialization of cost-effective generic drugs are some other factors driving this region’s growth. For instance, in 2015 Novartis AG received FDA approval to market Gleevec (imatinib) under a special protocol assessment (SPA).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising geriatric population base that increases their susceptibility towards various cancers such as ovarian and breast cancer along with growing awareness about early diagnosis among patients leading to higher treatment rates which ultimately drives demand for oxaliplatin injections over the forecast period.
Growth Factors:
- Increasing incidence of colorectal cancer: The incidence of colorectal cancer is increasing globally due to the changing lifestyle and dietary habits. This will drive the demand for oxaliplatin injection as a treatment option.
- Growing awareness about early diagnosis and treatment: There is an increasing awareness among people about the importance of early diagnosis and treatment for various diseases including cancer. This will boost the demand for oxaliplatin injection as a preferred treatment option.
- Technological advancements in chemotherapy: There have been significant advancements in chemotherapy over the past few years, which has led to better outcomes with fewer side effects. This will increase the adoption of oxaliplatin injection as a preferred chemotherapeutic agent worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oxaliplatin Injection Market Research Report
By Type
10ml:50mg, 10ml:100mg, Other
By Application
Ovarian Cancer, Breast Cancer, SCLC, Other
By Companies
Hospira(Pfizer), Bristol-Myers Squibb SA, Teva, Mylan, Taj Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Cisen Pharmaceutical, Yunnan Phytopharmaceutical, Hisun, Jiangsu Lianhuan Pharmaceutical, Yangzijiang Group, Shandong Ruiying, Shanghai Acebright Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Oxaliplatin Injection Market Report Segments:
The global Oxaliplatin Injection market is segmented on the basis of:
Types
10ml:50mg, 10ml:100mg, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Breast Cancer, SCLC, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hospira(Pfizer)
- Bristol-Myers Squibb SA
- Teva
- Mylan
- Taj Pharmaceuticals
- Fresenius Kabi
- Qilu Pharmaceutical
- Cisen Pharmaceutical
- Yunnan Phytopharmaceutical
- Hisun
- Jiangsu Lianhuan Pharmaceutical
- Yangzijiang Group
- Shandong Ruiying
- Shanghai Acebright Pharmaceuticals
Highlights of The Oxaliplatin Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10ml:50mg
- 10ml:100mg
- Other
- By Application:
- Ovarian Cancer
- Breast Cancer
- SCLC
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oxaliplatin Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oxaliplatin injection is a chemotherapy drug that is used to treat cancer. It works by killing cancer cells.
Some of the major players in the oxaliplatin injection market are Hospira(Pfizer), Bristol-Myers Squibb SA, Teva, Mylan, Taj Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Cisen Pharmaceutical, Yunnan Phytopharmaceutical, Hisun, Jiangsu Lianhuan Pharmaceutical, Yangzijiang Group, Shandong Ruiying, Shanghai Acebright Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oxaliplatin Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oxaliplatin Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oxaliplatin Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oxaliplatin Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oxaliplatin Injection Market Size & Forecast, 2020-2028
4.5.1 Oxaliplatin Injection Market Size and Y-o-Y Growth
4.5.2 Oxaliplatin Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10ml:50mg
5.2.2 10ml:100mg
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ovarian Cancer
6.2.2 Breast Cancer
6.2.3 SCLC
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oxaliplatin Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oxaliplatin Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10ml:50mg
9.6.2 10ml:100mg
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ovarian Cancer
9.10.2 Breast Cancer
9.10.3 SCLC
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10ml:50mg
10.6.2 10ml:100mg
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ovarian Cancer
10.10.2 Breast Cancer
10.10.3 SCLC
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10ml:50mg
11.6.2 10ml:100mg
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ovarian Cancer
11.10.2 Breast Cancer
11.10.3 SCLC
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10ml:50mg
12.6.2 10ml:100mg
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ovarian Cancer
12.10.2 Breast Cancer
12.10.3 SCLC
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10ml:50mg
13.6.2 10ml:100mg
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ovarian Cancer
13.10.2 Breast Cancer
13.10.3 SCLC
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oxaliplatin Injection Market: Competitive Dashboard
14.2 Global Oxaliplatin Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hospira(Pfizer)
14.3.2 Bristol-Myers Squibb SA
14.3.3 Teva
14.3.4 Mylan
14.3.5 Taj Pharmaceuticals
14.3.6 Fresenius Kabi
14.3.7 Qilu Pharmaceutical
14.3.8 Cisen Pharmaceutical
14.3.9 Yunnan Phytopharmaceutical
14.3.10 Hisun
14.3.11 Jiangsu Lianhuan Pharmaceutical
14.3.12 Yangzijiang Group
14.3.13 Shandong Ruiying
14.3.14 Shanghai Acebright Pharmaceuticals
